{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The integrity of the randomization code and corresponding blinded clinical supplies will be', 'maintained whenever possible. A serious adverse event or the potential for a product quality', 'problem existing beyond the scope of the complaint may be a reason to unblind the clinical', 'supplies for an affected patient.', '11.4.3.', 'Adverse Events or Serious Adverse Events Associated with a Product Complaint', 'If there is an adverse event or serious adverse event due to product complaint, the protocol', 'should be followed for recording and reporting (Section 7.1.2 and Section 7.1.5.3, respectively).', '11.4.4.', 'Documenting a Product Complaint', 'The investigator will record in the source documentation a description of the product complaint,', 'and any actions taken to resolve the complaint and to preserve the safety of the patient. Once the', 'complaint has been investigated by the sponsor and the investigator, if necessary, an event', 'closure letter may be sent to the investigational center where the complaint originated or to all', 'investigational centers using the product.', '11.5.', 'Audit and Inspection', 'The sponsor or delegate may audit the investigational center to evaluate study conduct and', 'compliance with protocols, SOPs, GCP guidelines, and applicable regulatory requirements. The', \"sponsor's Global Clinical Quality Assurance, independent of Global Clinical Development, is\", 'responsible for determining the need for (and timing of) an investigational center audit.', 'The investigator must accept that competent authorities and sponsor representatives may conduct', 'inspections and audits to verify compliance with GCP guidelines.', '106']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '12.', 'ETHICS', 'Details of compliance with regulatory requirements and applicable laws are provided in', 'Section 1.6.', '12.1.', 'Informed Consent/Assent', 'The investigator, or a qualified person designated by the investigator, should fully inform the', 'patient and parent/legally acceptable representative of all pertinent aspects of the study,', 'including the written information approved by the IEC/IRB. All written and oral information', 'about the study will be provided in a language as nontechnical as practical to be understood by', 'the parent/legally acceptable representative and the patient. The patient and parent/legally', 'acceptable representative should be given ample time and opportunity to inquire about details of', 'the study and to decide whether or not to participate in the study. The above should be detailed in', 'the source documents.', 'A personally signed and dated informed consent form will be obtained from parent/legally', \"acceptable representative, and a signed and dated assent, depending on the child's age, as\", 'appropriate, will be obtained from each patient (if the patient is able) before any study-specific', 'procedures or assessments are done and after the aims, methods, anticipated benefits, and', 'potential hazards are explained; according to national and local IEC/IRB requirements. The', 'forms will be signed and dated also by the person who conducted the informed consent', 'discussion. The investigator will keep the original informed consent/assent forms, depending on', \"the child's age, as appropriate, and copies will be given to the patients. It will also be explained\", 'to the patients (and parent/legally acceptable representative) that they are free to refuse', 'participation in the study and free to withdraw from the study at any time without prejudice to', 'future treatment.', '12.2.', 'Competent Authorities and Independent Ethics', 'Committees/Institutional Review Boards', 'Before this study starts, the protocol will be submitted to the national and local competent', 'authority and to each IEC/IRB for review. As required, the study will not start at a given', 'investigational center before the IEC/IRB and competent authority (where applicable) for the', 'investigational center give written approval or a favorable opinion.', '12.3.', 'Confidentiality Regarding Study Patients', 'The investigator must ensure that the privacy of the patients, including their identity and all', 'personal medical information, will be maintained at all times. In CRFs and other documents or', 'image material submitted to the sponsor, patients will be identified not by their names, but by an', 'identification number.', 'Personal medical information may be reviewed for the purpose of patient safety or for verifying', 'data in the source and transcribed to the CRF. This review may be conducted by the study', 'monitor, properly authorized persons on behalf of the sponsor, Global Quality Assurance, or', 'competent authorities. Personal medical information will always be treated as confidential.', '107']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '12.4.', 'Declaration of the End of Clinical Study', 'The end of study is defined as the date of the week 14 visit of the last participant.', 'For investigational centers located in the European Union, a declaration of the end of the clinical', 'study will be made according to the procedures outlined in Directive 2001/20/EC, Article 10(c);', 'for other countries, national and local regulations will be followed.', '12.5.', 'Registration of the Clinical Study', 'In compliance with national and local regulations and in accordance with Teva standard', 'procedures, this clinical study may be registered on clinical studies registry websites.', '108']\n\n###\n\n", "completion": "END"}